no fewer than 60 started to lay down fat early in pregnancy and all save two of them were prevented from laying down more unnecessary fat without any calorie control whatever, merely by cutting out sugar and sweet items of food and reducing the intake of products made from white flour. 
no fewer than 60 started to lay down fat early in pregnancy and all save two of them were prevented from laying down more unnecessary fat without any calorie control whatever, merely by cutting out sugar and sweet items of food and reducing the intake of products made from white flour.3 The average weight gain of the series, excluding toxaemic patients, was 10 0 kg (21-9 lb) as against the average uncontrolled weight gain in recent British series of 12-5 kg (27 5 lb), which Hytten and Leitch,4 from the Alberdeen team, estimate to include 3-5 kg (7 7 lb) of fat. Moreover 30 of my patients who were followed through a second pregnancy5 put on no weight between pregnancies on answer the important points he raises.
Our purpose was to present the plasma digoxin concentrations measured during satisfactory maintenance therapy of infants and children with cardiac failure. We agree that plasma levels achieved during initial digitalization should be measured in order to determine the optimum digitalizing dose.
This would require several samples of blood, and when we conducted our study 15 ml of plasma was necessary for each radioimmunoassay. We have now evolved a microassay requiring only 01-0-3 ml of plasma and are using this to determine the necessary digitalization dose in infants and children.
All our reported patients had moderate to severe cardiac failure with the clinical signs of tachycardia, tachypnoea, and hepatomegaly; some had pulmonary and peripheral oedema. An improvement in all these signs was indicative of a satisfactory clinical response.
Even in the presence of severe heart failure the oral maintenance dose was absorbed sufficiently to give plasma levels comparable to therapeutic adult levels. If oral or intragastric administration is not tolerated, it is our practice to give half the oral dose by the intramuscular route, but to date we have no measurement of the resulting plasma levels. The development of a microassay of digoxin will facilitate further studies of the infant's handling of this drug. - 
